AXE (ASX) AXE Chart

Originally posted by sabine: ↑

Thank you for sharing Saragian
And after seeing the deceptively simple and laser precise TA you have shared over at DRO I thought I’d wade in with an introductory ‘nutshell’ on AXE to accompany your ‘stalking’ chart for any others who follow your work and know nothing of the Archer fundamentals,

Cheers

This is a quick lfrom Stocks Down Under, a subsidiary of the advertorially-based research company Pitt Street Research, dated three weeks back

https://stocksdownunder.com/article/quantum-computing-stock-asx/

Archer Materials (ASX:AXE), the ASX’s only quantum computing stock, has made progress in the last 12 months
Nick Sundich, July 4, 2024

Archer Materials (ASX:AXE) has garnished significant investor attention as ASX’s only quantum computing stock.
It has been a rollercoaster ride for investors in the company, riding any perceived wins the company achieves but worrying when it is perceived the company (or the industry) has suffered a setback.

The reality is that development of such comprehensive technological devices is that it takes time, especially when the specific technology is at a nascent stage. However, the company has made significant progress of late.

Recap of Archer – the ASX’s only quantum computing stock

Archer is developing two technologies – 12CQ and Biochip. 12CQ is a carbon-based quantum bit (qubit) semiconductor technology.
Once fully developed, the technology may potentially enable quantum devices that process quantum information in mobile technology and be accessible to a more broader population than today.

Biochip is a Lab-on-a-Chip technology being developed to enable rapid, parallelised detection of diseases.
It would allow droplets of biological specimens to be analysed and processed using graphene sensors.

Investors curious for further detail on how these technologies work should read the research reports on Archer Materials from out parent company Pitt Street Research here.

Archer Materials’ achievements in 2024

We’re only half way through 2024, but it has been a year full of achievements.

In March 2024, the company designed a miniaturised version of Biochip for fabrication at a commercial foundry – from 10mm to 1.5mm.
This is big because it demonstrates Archer’s expertise, in being able to scale down chips so substantially while not just maintaining but enhancing performance – something that is not easy to do in a non-cost-prohibitive way.

Also in March 2024, developing a pulsed electron spin resonance (p-ESR) spectrometer on chip with its research partner EPFL (École Polytechnique Fédérale de Lausanne) based in Switzerland.
The big deal about this is that such a chip could detect and analyse the behaviour of unpaired electrons, by measuring ESR parameters such as spin-spin relaxation time and spin-lattice relaxation time.
These are important parameters for determining the time-window for processing electron spin information in solid-state quantum electronic devices.
Archer intends to use the p-ESR microsystem to perform complex measurements involving the potential electron spin manipulation of Archer’s 12CQ quantum materials.

In June, the company revealed the results of its Biochip designs with external foundry partners, and it was a complete success.
The fabrication produced 145 chips with 8gFET devices on each chip.

But didn’t Archer Materials miss out on a $940m investment?

Many investors would be disappointed when they heard media headlines that the government was investing in PsiQuantum.
Arguably, they thought the investment meant Archer was behind PsiQuantum, and perhaps some of its peers.
This is not the case – all quantum players are at an R&D phase and are at least a few years away form commercialisation.
Even companies like Microsoft and IBM, with established businesses, are still at an R&D phase with quantum.

Although the optics may appear to be a bet in PsiQuantum, this was part of the government’s budget to aid the quantum industry, and we expect the benefits to flow through to Archer, as well as its peers.
As part of the deal, PsiQuantum will establish a quantum innovation precinct, invest in university and research collaborations, as well as to create a dedicated climate research centre.
Investors may not realise that even though Archer employs its own staff, it is reliant on external facilities – like the Nanoscience Hub at the University of Sydney – for research.

Slow and steady will prevail

The reality with technology companies like Archer at an R&D phase is that it is a slow and measured grind. Development of 12CQ and Biochip will occur gradually over the rest of the decade, and commercialisation of any quantum devices is at least 5-7 years.
The ‘investment’ will reap benefits for Archer and the broader industry.

Investors in companies like Archer need to be patient and look past short-term headlines.
Even though it is too early to ascribe any valuation onto Archer, we think those with patience could be rewarded in the years to come.

The report from Pitt Street Research is an issuer-sponsored report.

Expand

I’d be really disappointed if it was really 7 years away.

No.	Vol.	Price($)
1	3000	22.0¢

No.

Vol.

Price($)

3000

22.0¢

Price($)	Vol.	No.
22.5¢	136558	6

Price($)

Vol.

No.

22.5¢

136558

No.	Vol.	Price($)
1	3000	0.220
2	8000	0.215
1	8000	0.205
2	24900	0.200
1	10000	0.195

No.

Vol.

Price($)

3000

0.220

8000

0.215

8000

0.205

24900

0.200

10000

0.195

Price($)	Vol.	No.
0.225	135458	5
0.230	67628	3
0.235	22447	2
0.240	86617	3
0.245	28172	2

Price($)

Vol.

No.

0.225

135458

0.230

67628

0.235

22447

0.240

86617

0.245

28172

(20min delay)
Last 22.5¢		Change 0.035(18.4%)		Mkt cap ! $57.34M

Open	High	Low	Value	Volume
19.5¢	22.5¢	19.5¢	$257.6K	1.237M

AXE Chart, page-210

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before it can buy Namoi Cotton

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

AXE Chart, page-210

Top Stories

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before it can buy Namoi Cotton

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News